FrancophonIA/ELRC3.0 huggingface dataset:
English: After completion of six cycles of carboplatin-paclitaxel chemotherapy or upon premature discontinuation of chemotherapy, patients on the bevacizumab + carboplatin-paclitaxel arm continued to receive bevacizumab as a single agent every 3 weeks until disease progression.
Croatian: Nakon završetka šest ciklusa kemoterapije s karboplatinom i paklitakselom ili preuranjenog prekida kemoterapije, bolesnici u skupini koja je primala bevacizumab
English: Median PFS (months) Hazard ratio (95% CI)
Croatian: Medijan PFS (mjeseci) Omjer hazarda (95% CI)
English: Erlotinib N = 77#
Croatian: N = 75#
English: Monitoring of proteinuria by dipstick urinalysis is recommended prior to starting and during therapy.
Croatian: Prije početka i tijekom liječenja bevacizumabom preporučuje se kontrola proteinurije analizom mokraće pomoću test trakica.
English: 130 mg/m2 IV 2 h
Croatian: 130 mg/m2 i.v. 2 h oksaliplatin 1. dana kapecitabin
English: • a hole in your gut wall,
Croatian: • u slučaju napuknuća u stijenci crijeva,
English: No clinically relevant interaction of co-administered chemotherapy on bevacizumab pharmacokinetics was observed based on the results of population pharmacokinetic analyses.
Croatian: Rezultati analiza populacijske farmakokinetike pokazali su da nema klinički značajnih interakcija istodobno primijenjene kemoterapije na farmakokinetiku bevacizumaba.
English: However, sleepiness and fainting have been reported with MVASI use.
Croatian: Međutim, pri primjeni lijeka MVASI prijavljene su pospanost i nesvjestica.
English: Hazard ratio
Croatian: Omjer rizika
English: Rate
Croatian: Stopa
English: N Response rate
Croatian: Razlika u stopama odgovora
English: • blockage in the gut or bowel,
Croatian: • zastoj rada crijeva,
English: Asthenia, Fatigue, Pyrexia, Pain,
Croatian: Opći poremećaji i reakcije na mjestu primjene astenija, umor, pireksija, bol, upala sluznice letargija
English: No increase in the incidence of other reactions, including gastrointestinal perforation, wound healing complications, congestive heart failure, and haemorrhage was observed in elderly patients (> 65 years) receiving bevacizumab as compared to those aged ≤ 65 years treated with bevacizumab.
Croatian: U starijih bolesnika (> 65 godina) koji su primali bevacizumab, u odnosu na bolesnike u dobi od ≤ 65 godina liječene bevacizumabom, nije primijećen porast incidencije drugih reakcija, uključujući gastrointestinalne perforacije, komplikacije pri zacjeljivanju rana, kongestivno zatajenje srca i krvarenje.
English: Endpoint (months)
Croatian: percentil (mjeseci)
English: Increased rates of severe neutropenia, febrile neutropenia, or infection with or without severe neutropenia (including some fatalities) have been observed in patients treated with some myelotoxic chemotherapy regimens plus bevacizumab in comparison to chemotherapy alone.
Croatian: U bolesnika liječenih nekim mijelotoksičnim kemoterapijskim protokolima u kombinaciji s bevacizumabom su, u usporedbi s primjenom samo kemoterapije, opažene povećane stope teške neutropenije, febrilne neutropenije te infekcije praćene teškom neutropenijom ili bez nje (s nekoliko smrtnih ishoda).
English: Posterior reversible encephalopath y syndromea,b,c, Hypertensive encephalopath yc
Croatian: Poremećaji reproduktivnog sustava i dojki zatajivanje jajnikab,c,d bol u zdjelici
English: Capecitabine oral bid for 2 weeks (followed by 1 week off treatment)
Croatian: 1000 mg/m2 peroralno dva puta na dan kapecitabin, peroralno, dva puta na dan tijekom 2 tjedna (slijedi jednotjedni prekid)
English: Median PFS (months) Hazard ratio (95% CI)4 Randomised patients with stage IV disease CPP (n = 153)
Croatian: Randomizirane bolesnice sa stadijem IV bolesti CPP (n = 153)
English: Haemorrhagea,b, Thromboembolis m (venous)a,b,
Croatian: Krvožilni poremećaji hipertenzijaa,b tromboembolija (arterijska)a,b, krvarenjea,b, tromboembolija (venska)a,b, duboka venska tromboza bubrežna trombotska mikroangiopatijab,c aneurizme i disekcije arterije
English: A large phase III trial was designed to investigate the treatment effect of bevacizumab in combination with paclitaxel, as measured by the primary endpoint of PFS. A clinically meaningful and statistically significant improvement in PFS was observed.
Croatian: Djelotvornost liječenja bevacizumabom u kombinaciji s paklitakselom ispitana je u velikom ispitivanju faze III, u kojima je primarna mjera ishoda bilo preživljenje bez progresije bolesti.
English: Caution should be taken when treating these patients with MVASI.
Croatian: Kad se takvi bolesnici liječe lijekom MVASI, potreban je oprez.
English: These patients often do not have other treatment options.
Croatian: Ti bolesnici često nemaju druge mogućnosti liječenja.
English: Treatment is continued for 6 weeks, but may be extended for up to another 6 weeks if needed.
Croatian: Liječenje traje šest tjedana, a prema potrebi može se produžiti najviše još šest tjedana.
English: The recommended dose is one tablet twice a day.
Croatian: Preporučena je doza jedna tableta dvaput dnevno.
English: Tablets must not be chewed or swallowed whole.
Croatian: Tablete se ne smiju žvakati niti cijele progutati.
English: Jorveza budesonide
Croatian: Jorveza budezonid
English: What measures are being taken to ensure the safe and effective use of Jorveza?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Jorveza?
English: After 6 weeks, around 58% of the patients taking Jorveza (34 out of 59 patients) had reduced eosinophils and no symptoms or only minimal symptoms, whereas none of the 29 patients taking placebo had these effects.
Croatian: Nakon šest tjedana oko 58 % bolesnika koji su primali lijek Jorveza (34 od 59 bolesnika) imalo je niže koncentracije eozinofila te nije imalo nikakvih simptoma ili su simptomi bili vrlo blagi, dok ni kod jednog od 29 bolesnika koji su primali placebo nisu zabilježeni takvi učinci.
English: What is Jorveza and what is it used for?
Croatian: Što je Jorveza i za što se koristi?
English: The tablet is placed on the tongue and pressed against the roof of the mouth for around two minutes until it dissolves.
Croatian: Tableta se stavi na jezik, pritisne o nepce i tako drži oko dvije minute sve dok se potpuno ne otopi.
English: The European Medicines Agency decided that Jorveza's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Jorveza nadmašuju s njim povezane rizike te je preporučila davanje odobrenja za njegovu primjenu u EU-u.
English: This is a summary of the European public assessment report (EPAR) for Jorveza.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Jorveza.
English: Other information about Jorveza
Croatian: Ostale informacije o lijeku Jorveza
English: It is not intended to provide practical advice on how to use Jorveza.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Jorveza.
English: The full EPAR for Jorveza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Jorveza nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What are the risks associated with Jorveza?
Croatian: Koji su rizici povezani s lijekom Jorveza?
English: Side effects with Jorveza are mainly the same as those of other similar medicines.
Croatian: Nuspojave lijeka Jorveza uglavnom su iste kao i nuspojave drugih sličnih lijekova.
English: Jorveza is available as orodispersible tablets (1 mg).
Croatian: Lijek Jorveza dostupan je u obliku raspadljivih tableta za usta (1 mg).
English: Why is Jorveza approved?
Croatian: Zašto je lijek Jorveza odobren?
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Jorveza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Croatian: Sažetak mišljenja Odbora za lijekove za rijetke bolesti o lijeku Jorveza nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Jorveza have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Jorveza nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: Because the number of patients with eosinophilic oesophagitis is low, the disease is considered ‘rare', and Jorveza was designated an ‘orphan medicine' (a medicine used in rare diseases) on 5 August
Croatian: Budući da je broj bolesnika s eozinofilnim ezofagitisom nizak, bolest se smatra „rijetkom” te je lijek Jorveza dobio status „lijeka za liječenje rijetkih bolesti” 5. kolovoza 2013.
English: Corticosteroids help reduce inflammation by attaching to receptors of immune cells and reducing the release of substances that are involved in the inflammation process.
Croatian: Kortikosteroidi pomažu pri ublažavanju upale vezivanjem na receptore imunosnih stanica te na taj način smanjuju oslobađanje tvari koje sudjeluju u upalnom procesu.
English: The most common side effects with Jorveza (which may affect up to 3 in 10 people) are fungal infections in the mouth, pharynx (throat) and oesophagus.
Croatian: Najčešće su nuspojave lijeka Jorveza (koje se mogu javiti u do 3 na 10 osoba) gljivične infekcije u ustima, grlu (ždrijelu) ili jednjaku.
English: The active substance in Jorveza, budesonide, is a corticosteroid medicine.
Croatian: Djelatna tvar lijeka Jorveza je budezonid, kortikosteroidni lijek.
English: For more information about treatment with Jorveza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Jorveza pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svojem liječniku ili ljekarniku.
English: The main measure of effectiveness was the level of eosinophils in the oesophagus and improvement in symptoms.
Croatian: Glavna mjera učinkovitosti bila je koncentracije eozinofila u jednjaku i stupanj ublažavanja simptoma.
English: Jorveza was compared with placebo (a dummy treatment).
Croatian: Lijek Jorveza uspoređen je s placebom (prividnim liječenjem).
English: It is caused by a large build-up of white blood cells called eosinophils in the lining of the oesophagus.
Croatian: Uzrokovan je stvaranjem velikog broja bijelih krvnih stanica, tj. eozinofila, u stijenci jednjaka.
English: Jorveza was shown to be effective in one main study involving 88 adults with eosinophilic oesophagitis.
Croatian: Lijek Jorveza pokazao se učinkovitim u jednom glavnom ispitivanju kojim je bilo obuhvaćeno 88 odraslih bolesnika s eozinofilnim ezofagitisom.
English: For practical information about using Jorveza, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Jorveza bolesnici trebaju pročitati u uputi o lijeku, odnosno trebaju se obratiti svojem liječniku ili ljekarniku.
English: For the full list of all side effects and restrictions with Jorveza, see the package leaflet.
Croatian: Potpuni popis svih nuspojava i ograničenja prilikom primjene lijeka Jorveza potražite u uputi o lijeku.
English: Jorveza benefits patients with eosinophilic oesophagitis by improving the symptoms of the disease and reducing the excess of eosinophils.
Croatian: Jorveza koristi bolesnicima s eozinofilnim ezofagitisom jer ublažava simptome bolesti i snižava prekomjerne razine eozinofila.
English: Jorveza can only be obtained with a prescription and treatment should be started by a doctor experienced with diagnosing and treating eosinophilic oesophagitis.
Croatian: Jorveza se izdaje samo na liječnički recept, a liječenje treba započeti liječnik s iskustvom u dijagnosticiranju i liječenju eozinofilnog ezofagitisa.
English: How is Jorveza used?
Croatian: Kako se Jorveza koristi?
English: How does Jorveza work?
Croatian: Kako djeluje Jorveza?
English: What benefits of Jorveza have been shown in studies?
Croatian: Koje su koristi lijeka Jorveza utvrđene u ispitivanjima?
English: Jorveza contains the active substance budesonide.
Croatian: Jorveza sadržava djelatnu tvar budezonid.
English: Jorveza is a medicine used to treat adults with eosinophilic oesophagitis.
Croatian: Jorveza je lijek koji se koristi za liječenje odraslih osoba oboljelih od eozinofilnog ezofagitisa.
English: During this time the patient should steadily swallow the saliva with the dissolved medicine.
Croatian: Dok se tableta raspada, bolesnik treba pomalo gutati slinu s otopljenim lijekom.
English: Eosinophilic oesophagitis is inflammation of the oesophagus (the food-pipe that leads from the mouth to the stomach), which causes symptoms including dysphagia (difficulty swallowing) and obstruction of the oesophagus.
Croatian: Eozinofilni ezofagitis je upala jednjaka (ezofagusa) koja uzrokuje simptome poput disfagije (otežanog gutanja) i začepljenje jednjaka.
English: After Jorveza dissolves in the mouth, the saliva carries it to the oesophagus where it reduces the inflammation and relieves the symptoms of eosinophilic oesophagitis.
Croatian: Nakon što se lijek Jorveza otopi u ustima, slinom se prenosi u jednjak te ublažava upalu i simptome eozinofilnog ezofagitisa.
English: 50000 IU Powder and solvent for solution for injection
Croatian: NeoRecormon 50000 IU Prašak i otapalo za otopinu za injekciju
English: Subcutaneous or intravenous use powder: multidose vial (glass); solvent: ampoule (glass)
Croatian: Za primjenu potkožno ili u venu prašak: višedozna bočica (staklo); otapalo: ampula (staklo)
English: 1 vial + 1 ampoule
Croatian: 1 bočica + 1
English: solvent: 10 ml (reconst.
Croatian: otapalo: 10 ml (rekonst. otopina 5000 IU/ml)
English: MYLAN SAS 117, allée des Parcs 69800 Saint-Priest France
Croatian: Francuska MYLAN SAS 117, allée des Parcs 69800 Saint-Priest France
English: Oficina D 28230 Las Rozas (Madrid) Spain
Croatian: 28230 Las Rozas (Madrid) Spain
English: 11-15 Quai Dion Bouton 92800 Puteaux France
Croatian: 11-15 Quai Dion Bouton 92800 Puteaux
English: Germany Hexal Aktiengesellschaft Industriestr.
Croatian: Njemačka Hexal Aktiengesellschaft Industriestr.
English: Desitin Arzneimittel GmbH Postfach 630164
Croatian: Norveška Desitin Arzneimittel GmbH Postfach 630164
English: ARENA GROUP S.A. Str. Ştefan Mihăileanu nr.
Croatian: Rumunjska S.C. ARENA GROUP S.A. Str. Ştefan Mihăileanu nr.
English: Luxembourg Hexal AG Industriestrasse 25 83067 Holzkirchen Germany
Croatian: Luksemburg Hexal AG Industriestrasse 25 83067 Holzkirchen Germany
English: DK-2970 Hørsholm
Croatian: DK-2970 Hørsholm Denmark
English: Germany IIP - Institut für industrielle Pharmazie Forschungs- und Entwicklungsgesellschaft mbH
Croatian: Njemačka IIP - Institut für industrielle Pharmazie Forschungs- und Entwicklungsgesellschaft mbH
English: Luxembourg Eurogenerics SA Esplanade Heysel b22
Croatian: Luksemburg Eurogenerics SA Esplanade Heysel b22
English: Sweden Sanofi AB Box 30052
Croatian: Sanofi AB Box 30052
English: PSC 170 00 Holesovice Czech Republic
Croatian: PSC 170 00 Holesovice Czech Republic magnezijev valproat
English: Kampenringweg 45 D-E 2803 PE GOUDA The Netherlands
Croatian: Kampenringweg 45 D-E 2803 PE GOUDA
English: 110, Esplanade du Général de Gaulle
Croatian: Francuska TEVA SANTE 110, Esplanade du Général de Gaulle
English: Arrow Generiques 26, avenue Tony Garnier 69007 Lyon
Croatian: Francuska Arrow Generiques 26, avenue Tony Garnier 69007 Lyon
English: Finland Sanofi Oy Huopalahdentie 24 PL 22
Croatian: Sanofi Oy Huopalahdentie 24 PL 22
English: Laboratoire AGUETTANT 1, rue Alexander Fleming 69007 Lyon
Croatian: Francuska Laboratoire AGUETTANT 1, rue Alexander Fleming 69007 Lyon
English: SANOFI AVENTIS, S.A. Josep Plá, 2
Croatian: Španjolska SANOFI AVENTIS, S.A. Josep Plá, 2
English: Austria sanofi-aventis GmbH SATURN Tower, Vienna DC Leonard-Bernstein-Straße
Croatian: Austrija sanofi-aventis GmbH SATURN Tower, Vienna DC Leonard-Bernstein-Straße
English: Latvia sanofi-aventis Latvia SIA Kr.Valdemara 33-8 Riga LV1010
Croatian: Latvija sanofi-aventis Latvia SIA Kr.Valdemara 33-8 Riga LV1010
English: Luxembourg Takeda Belgium Chaussée de Gand 615 1080 Bruxelles
Croatian: Luksemburg Takeda Belgium Chaussée de Gand 615 1080 Bruxelles
English: Finland Sandoz A/S C. F. Tietgens Boulevard 40 5220 ODENSE SØ Denmark
Croatian: C. F. Tietgens Boulevard 40 5220 ODENSE SØ Denmark
English: Sandoz B.V. Veluwezoom 22 1327 AH ALMERE The Netherlands
Croatian: Veluwezoom 22 1327 AH ALMERE The Netherlands
English: Centrafarm B.V. Nieuwe Donk 3 4879 AC ETTEN LEUR The Netherlands
Croatian: Nieuwe Donk 3 4879 AC ETTEN LEUR The Netherlands
English: Lithuania UAB „SANOFI-AVENTIS LIETUVA“
Croatian: UAB „SANOFI-AVENTIS LIETUVA“
English: Luxembourg Mylan BVBA/SPRL Terhulpsesteenweg 6 box A 1560 Hoeilaart
Croatian: Luksemburg Mylan BVBA/SPRL Terhulpsesteenweg 6 box A 1560 Hoeilaart
English: Evropská 846/176a 160 00 Prague 6
Croatian: Sanofi-Aventis, s.r.o. Evropská 846/176a 160 00 Prague 6
English: Germany 1 A Pharma GmbH Keltenring 1 + 3
Croatian: Njemačka 1 A Pharma GmbH Keltenring 1 + 3
English: Ranbaxy Pharmacie Génériques
Croatian: Francuska Ranbaxy Pharmacie Génériques
English: Luxembourg Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem
Croatian: Luksemburg Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem
English: Denmark Sanofi-aventis Denmark A/S
Croatian: Sanofi-aventis Denmark A/S
English: D-22311 HAMBURG Deutschland
Croatian: D-22311 HAMBURG
English: Sanofi-Aventis Netherlands B.V.
Croatian: Nizozemska Sanofi-Aventis Netherlands B.V.
English: Germany Sanofi-Aventis Deutschland GmbH
Croatian: Njemačka Sanofi-Aventis Deutschland GmbH
English: Convulsofin Tabletten
Croatian: Convulsofin Tabletten tablet
English: Denmark Sandoz A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark
Croatian: Edvard Thomsens Vej 14 DK-2300 København
English: Germany Stadapharm GmbH Stadastr 2-18
Croatian: Njemačka Stadapharm GmbH Stadastr 2-18
English: Germany Mylan dura GmbH Wittichstr.
Croatian: Njemačka Mylan dura GmbH Wittichstr.
English: 02101 Espoo
Croatian: 02101 Espoo Finland
English: Apotex Europe B.V. Darwinweg 20 2333 CR LEIDEN The Netherlands
Croatian: Darwinweg 20 2333 CR LEIDEN The Netherlands
English: Sanofi-Aventis Bulgaria EOOD
Croatian: Bugarska Sanofi-Aventis Bulgaria EOOD
English: Depakine sirop
Croatian: Depakine sirup
English: Via Scarlatti Domenico, 31 20124 Milano Italy
Croatian: Via Scarlatti Domenico, 31 20124 Milano Italy valproatna kiselina, natrijev valproat
English: Teva Nederland B.V. Swensweg 5 2031 GA HAARLEM The Netherlands
Croatian: Swensweg 5 2031 GA HAARLEM The Netherlands
English: Sanofi-Aventis zrt.
Croatian: Mađarska Sanofi-Aventis zrt.
English: Germany Dolorgiet GmbH & Co.KG Otto-von-Guericke-Str. 1
Croatian: Njemačka Dolorgiet GmbH & Co.KG Otto-von-Guericke-Str.
English: Belgium Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem
Croatian: Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem Belgium
English: Orlept (SF) Liquid or Sodium Valproate 40mg/ml oral solution
Croatian: Orlept (SF) Liquid or Sodium Valproate 40mg/ml oral solution oralna otopina
English: Belgium Mylan BVBA/SPRL Terhulpsesteenweg 6 box A 1560 Hoeilaart
Croatian: Mylan BVBA/SPRL Terhulpsesteenweg 6 box A 1560 Hoeilaart Belgium
English: Depakine vloeistof voor kinderen, vloeistof voor oraal gebruik 300 mg/ml
Croatian: Depakine vloeistof voor kinderen, vloeistof voor oraal gebruik 300 mg/ml oralna tekućina
English: Syrup
Croatian: sirup
English: Germany Orion Corporation Orionintie 1 A
Croatian: Njemačka Orion Corporation Orionintie 1 A
English: 500-1000 mg Modified-release granules
Croatian: 500-1000 mg granule s prilagođenim oslobađanjem
English: Germany ALIUD PHARMA GmbH Gottlieb-Daimler-Str. 19
Croatian: Njemačka ALIUD PHARMA GmbH Gottlieb-Daimler-Str. 19
English: LT-09310 Vilnius
Croatian: Juozapavičiaus g. 6/2 LT-09310 Vilnius Lithuania
English: Valproinsäure- ratiopharm Lösung
Croatian: Valproinsäure- ratiopharm Lösung oralna otopina
English: Germany Neuraxpharm Arzneimittel GmbH
Croatian: Njemačka Neuraxpharm Arzneimittel GmbH
English: Valproic acid Ácido Valpróico Generis
Croatian: Ácido Valpróico Generis
English: DEMO ABEE 21st Km Athens-Lamias National Highway 14568 Kryoneri Greece
Croatian: National Highway 14568 Kryoneri Greece
English: Depakine suikervrije stroop, drank 200 mg/5 ml
Croatian: Depakine suikervrije stroop, drank 200 mg/5 ml oralna otopina
English: Sanofi-Aventis Croatia d.o.o.
Croatian: Hrvatska Sanofi-Aventis Croatia d.o.o.
English: Finland Orion Pharma Orionintie 1
Croatian: Orion Pharma Orionintie 1 PL 65
English: Romania Sanofi-Aventis France 1-13 Boulevard Romain Rolland
Croatian: Rumunjska Sanofi-Aventis France 1-13 Boulevard Romain Rolland
English: LABORATOIRES ALTER 3, avenue de la Baltique, ZI de Courtaboeuf 91140 Villebon Sur Yvette France
Croatian: Francuska LABORATOIRES ALTER 3, avenue de la Baltique, ZI de Courtaboeuf
English: DEPAKINE 57,64 mg/ml, sirop 57.64 mg
Croatian: DEPAKINE 57,64 mg/ml, sirop 57,64 mg sirup
English: Valpro TAD Lösung
Croatian: Valpro TAD Lösung oralna otopina
English: 17 Bonifraterska Str. 00-203 Warsaw Poland
Croatian: Sanofi-Aventis Sp. z o.o. 17 Bonifraterska Str. 00-203 Warsaw Poland
English: Germany Winthrop Arzneimittel GmbH
Croatian: Njemačka Winthrop Arzneimittel GmbH
English: Germany betapharm Arzneimittel GmbH
Croatian: Njemačka betapharm Arzneimittel GmbH
English: Epilim 100mg Crushable Tablet
Croatian: Epilim 100mg Crushable Tablet tableta
English: 1000 Ľubľana Slovenia
Croatian: 1000 Ljubljana
English: Epilim 100 mg Crushable Tablets
Croatian: Epilim 100 mg Crushable Tablets tableta
English: VALPROATE DE SODIUM AGUETTANT 400 mg/4 ml, solution injectable
Croatian: VALPROATE DE SODIUM AGUETTANT 400 mg/4 ml, solution injectable otopina za injekciju u venu
English: Valproic acid VALPROATE SODIUM SANDOZ 500MG
Croatian: VALPROATE SODIUM SANDOZ 500MG
English: Modified-release tablet
Croatian: tableta s prilagođenim oslobađanjem
English: Depakine Chronosphere 250 166.76 mg 72.61 mg
Croatian: Depakine Chronosphere 250 166,76 mg + 72,61 mg granule s produljenim oslobađanjem
English: Epilim 400mg Powder & solvent for solution for injection
Croatian: Epilim 400mg Powder & solvent for solution for injection prašak za injekciju u venu
English: Sodium Valproate Oral solution BP 200mg/5ml
Croatian: Sodium Valproate Oral solution BP 200mg/5ml oralna otopina
English: Depakine Chronosphere 750 500,06 mg 217,75 mg
Croatian: Depakine Chronosphere 750 500,06 mg + 217,75 mg granule s produljenim oslobađanjem
English: Convulex 50 mg/ml syrup 50 mg/ml
Croatian: Convulex 50 mg/ml syrup 50 mg/ml sirup
English: Depakine 57,64 mg/ml syrup 57.64 mg/ml
Croatian: Depakine 57,64 mg/ml syrup 57,64 mg/ml sirup
English: Sodium valproate liquid 200mg/5ml
Croatian: Sodium valproate liquid 200mg/5ml oralna otopina
English: Depakine Chronosphere 100 66,66 mg 29.03 mg
Croatian: Depakine Chronosphere 100 66,66 mg + 29,03 mg granule s produljenim oslobađanjem
English: Depakine Enteric 150 mg 150 mg
Croatian: Depakine Enteric 150 mg 150 mg tablet
English: Depakine Chronosphere 1000 666,60 mg 290.27 mg
Croatian: Depakine Chronosphere 1000 666,60 mg + 290,27 mg granule s produljenim oslobađanjem
English: Depakine Chrono 500, tabletten met gereguleerde afgifte 500 mg
Croatian: Depakine Chrono 500, tabletten met gereguleerde afgifte 500 mg tableta s prilagođenim oslobađanjem
English: Magnesium Valproate
Croatian: Italy magnezijev valproat
English: Romania Desitin Arzneimittel Gmbh Weg beim Jaeger 214
Croatian: Rumunjska Desitin Arzneimittel Gmbh Weg beim Jaeger 214
English: Natriumvalproaat Apotex 300 mg/5 ml, drank
Croatian: Natriumvalproaat Apotex 300 mg/5 ml, drank oralna otopina
English: Convulex 100 mg/ml solution for injection/concentrate for solution for infusion
Croatian: Convulex 100 mg/ml solution for injection/concentrate for solution for infusion otopina za injekciju/infuziju u venu